MaxCyte (LSE:MXCT) Institutional Ownership : 44.92% (As of May. 28, 2024)

View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MaxCyte's institutional ownership is 44.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MaxCyte's Insider Ownership is 1.66%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MaxCyte's Float Percentage Of Total Shares Outstanding is 99.15%.

MaxCyte Institutional Ownership Historical Data

The historical data trend for MaxCyte's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Institutional Ownership Chart

MaxCyte Historical Data

The historical data trend for MaxCyte can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	51.96	51.46	50.49	48.12	47.88	47.57	46.12	45.92	45.14	44.92

MaxCyte Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

MaxCyte (LSE:MXCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MXCT:USA MYE0:Germany

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.